Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2003
Small molecule inhibitors of cell signaling: novel future therapeutics for asthma and chronic obstructive pulmonary diseasesKate Blease, Heather K Raymon
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging treatments for asthmaKate Blease, Alan Lewis, Heather K Raymon
The Journal of Biological Chemistry|July 30, 2002
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell lineJulie Lotharius, Sebastian Barg, Pia Wiekop, et al.
Oncotarget|November 2, 2017
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitroToshiya Tsuji, Lisa M Sapinoso, Tam Tran, et al.
Bioorganic & Medicinal Chemistry|September 30, 2011
1,1-Diarylalkenes as anticancer agents: dual inhibitors of tubulin polymerization and phosphodiesterase 4Alexander L Ruchelman, Hon-Wah Man, Roger Chen, et al.
Cytotherapy|July 20, 2026
High affinity CD16v/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseasesLisa Guerrettaz, Paul Rogers, Gina Chu, et al.
Cancer Immunology, Immunotherapy : CII|July 11, 2021
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibodyRama Krishna Narla, Hardik Modi, Daniel Bauer, et al.
Cancer Research|January 21, 2006
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activityLing-Hua Zhang, Lei Wu, Heather K Raymon, et al.
Molecular Cancer Therapeutics|June 6, 2018
Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S CheckpointDan Zhu, Shuichan Xu, Gordafaried Deyanat-Yazdi, et al.
British Journal of Haematology|February 26, 2016
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myelomaEmily Rychak, Derek Mendy, Tao Shi, et al.
Pageof 2